Skip to main content
Premium Trial:

Request an Annual Quote

Celera and Ipsen to Develop Biomarkers, PGx Tests for Growth Failure Therapies

NEW YORK (GenomeWeb News) - Celera will help Ipsen develop pharmacogenomic tests that could be used in tandem with Ipsen’s hormone-replacement therapies for short stature, the companies said yesterday.
Under the first phase of the multi-year collaboration, Celera will work with the Paris-based specialty pharmaceutical company to locate and characterize genetic markers related to growth failure.
Should those efforts produce successful results, the companies will then develop diagnostic predictors that Ipsen could use in clinical trials. These predictors would then “potentially form the basis for commercial companion diagnostic tests for Ipsen's short stature therapies,” the companies said.
Ipsen will pay Celera an undisclosed sum for the initial phase of the collaboration. Any future payments will depend on the success of the initial phase.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.